Ceftriaxone (Rocephin) is significantly more likely to cause hemolytic anemia than hydralazine.
Ceftriaxone carries an explicit FDA warning for immune-mediated hemolytic anemia with documented severe and fatal cases, while hydralazine's primary hematologic concern is drug-induced lupus, not hemolytic anemia.
Evidence Hierarchy
Ceftriaxone (Rocephin) - High Risk
The FDA drug label explicitly warns that "an immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone" and that "severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children" 1. The label mandates that if anemia develops during ceftriaxone therapy, cephalosporin-associated anemia should be considered and the drug stopped until etiology is determined 1.
Recent case reports from 2024-2026 document the severity and rapidity of ceftriaxone-induced hemolytic anemia:
- A 78-year-old woman developed fulminant hemolysis with disseminated intravascular coagulation within 30 minutes of ceftriaxone administration, resulting in death within 8 hours 2
- A 5-year-old developed severe hemolysis with hemoglobin dropping to critical levels, requiring multiple transfusions and plasma exchange 3
- A 10-year-old's hemoglobin plummeted from 12.9 to 2.6 g/dL within 4 days of ceftriaxone/cefuroxime therapy, causing hypovolemic shock 4
The mechanism is drug-induced immune hemolytic anemia (DIIHA), where ceftriaxone-dependent antibodies target red blood cells, confirmed by positive direct antiglobulin tests (DAT) 2, 3, 4, 5, 6.
Hydralazine - Lower Risk
While hydralazine's FDA label mentions "blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, and purpura" 7, these are general hematologic abnormalities, not specifically immune-mediated hemolytic anemia.
The cardiovascular guidelines 8, 9, 10 note hydralazine is "associated with drug-induced lupus-like syndrome at higher doses" but do not highlight hemolytic anemia as a primary concern.
Historical data from 1979 indicates that "autoimmune hemolytic anemia is more common during treatment with alpha-methyldopa" compared to hydralazine, where the primary autoimmune concern is antinuclear antibodies and SLE-like syndrome 11. Hydralazine-induced lupus occurs predominantly in slow acetylators and is typically reversible after drug withdrawal 11.
Clinical Implications
For ceftriaxone:
- Monitor hemoglobin levels during therapy
- Immediately discontinue if acute hemolysis develops (pallor, tachycardia, hemoglobinuria, rapid Hb drop)
- Consider DAT testing if anemia develops
- Be aware that hemolysis can occur within hours to days and can be fatal
- Previous tolerance does not preclude future reactions 4
For hydralazine:
- Primary monitoring focuses on antinuclear antibodies and lupus symptoms (arthralgia, fever, chest pain)
- Complete blood counts are recommended periodically, but hemolytic anemia is not the expected hematologic complication 7
- Blood dyscrasias when they occur are typically cytopenias rather than immune-mediated hemolysis
Common Pitfall
Do not assume that hemolysis in a recently transfused patient is solely due to delayed hemolytic transfusion reaction—ceftriaxone-induced hemolytic anemia can masquerade as transfusion reaction, and the drug must be considered and discontinued 6.